[go: up one dir, main page]

PL3472177T3 - Oczyszczanie przeciwciał wieloswoistych - Google Patents

Oczyszczanie przeciwciał wieloswoistych

Info

Publication number
PL3472177T3
PL3472177T3 PL17751870.1T PL17751870T PL3472177T3 PL 3472177 T3 PL3472177 T3 PL 3472177T3 PL 17751870 T PL17751870 T PL 17751870T PL 3472177 T3 PL3472177 T3 PL 3472177T3
Authority
PL
Poland
Prior art keywords
purification
multispecific antibodies
multispecific
antibodies
Prior art date
Application number
PL17751870.1T
Other languages
English (en)
Inventor
Glen Scott GIESE
Eva Rosenberg
Bernard SALLIER
Susanne KONRAD
Wolfgang Koehnlein
Steffen Willmann
Agathe BIALAS
Kimberly Ann Kaleas-Carroll
Yinges Yigzaw
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3472177T3 publication Critical patent/PL3472177T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Water Supply & Treatment (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL17751870.1T 2016-06-17 2017-06-16 Oczyszczanie przeciwciał wieloswoistych PL3472177T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351908P 2016-06-17 2016-06-17
PCT/US2017/038007 WO2017218977A2 (en) 2016-06-17 2017-06-16 Purification of multispecific antibodies

Publications (1)

Publication Number Publication Date
PL3472177T3 true PL3472177T3 (pl) 2024-11-25

Family

ID=59593150

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17751870.1T PL3472177T3 (pl) 2016-06-17 2017-06-16 Oczyszczanie przeciwciał wieloswoistych

Country Status (18)

Country Link
US (1) US20190256556A1 (pl)
EP (1) EP3472177B1 (pl)
JP (3) JP2019521986A (pl)
KR (2) KR20190039929A (pl)
CN (1) CN109563124A (pl)
AR (1) AR108800A1 (pl)
AU (2) AU2017286676B2 (pl)
BR (1) BR112018075516A2 (pl)
CA (1) CA3026518A1 (pl)
ES (1) ES2988363T3 (pl)
HR (1) HRP20241323T1 (pl)
HU (1) HUE068564T2 (pl)
IL (1) IL263690B2 (pl)
MX (2) MX2018015173A (pl)
PL (1) PL3472177T3 (pl)
SG (1) SG11201810777WA (pl)
TW (1) TWI798179B (pl)
WO (1) WO2017218977A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. ANTIBODIES AND CONJUGATES THEREOF
US11964998B2 (en) * 2017-08-30 2024-04-23 Fresenius Kabi Deutschland Gmbh Method for purifying anti-IL-6 receptor antibodies
CN111491951B (zh) * 2017-12-22 2024-05-24 豪夫迈·罗氏有限公司 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
WO2019149691A1 (en) * 2018-01-30 2019-08-08 Univercells S.A. Protein purification process
WO2019149693A1 (en) * 2018-01-30 2019-08-08 Univercells S.A. Protein purification process and platform
IL276383B2 (en) * 2018-02-06 2024-01-01 Hoffmann La Roche Treatment of ophthalmological diseases
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
EA202192108A1 (ru) * 2019-01-28 2021-10-21 Эмджен Инк. Непрерывный способ изготовления для изготовления биопрепаратов посредством интеграции процессов получения лекарственного вещества и лекарственного препарата
CA3128027A1 (en) * 2019-01-29 2020-08-06 Shire-Nps Pharmaceuticals, Inc. Parathyroid hormone variants
JP2022531317A (ja) * 2019-05-03 2022-07-06 ジェネンテック， インコーポレイテッド 精製プラットフォームから得られた組成物中の酵素加水分解活性速度を低下させる方法
WO2020258704A1 (zh) * 2019-06-28 2020-12-30 信达生物制药(苏州)有限公司 无缝连续流层析方法
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
IL292602A (en) * 2019-11-07 2022-07-01 Amgen Inc High salt washes during cation exchange chromatography to remove product-related impurities
IL294545A (en) * 2020-01-15 2022-09-01 Hoffmann La Roche Methods to decrease impurities from recombinant protein manufacturing processes
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2021170060A1 (en) * 2020-02-28 2021-09-02 Wuxi Biologics (Shanghai) Co., Ltd. Purification of bispeciifc antibodies
CN115734969A (zh) * 2020-04-13 2023-03-03 上海药明生物技术有限公司 双特异性抗体的纯化
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
CA3182315A1 (en) * 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of affinity chromatography
AU2021262609A1 (en) * 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
CN114014906B (zh) * 2020-06-24 2024-01-12 夏尔巴生物技术(苏州)有限公司 一种利用阳离子交换层析纯化疏水性蛋白的方法
CN114539416B (zh) * 2020-11-26 2024-11-08 盛禾(中国)生物制药有限公司 一种双特异性抗体的层析纯化工艺
EP4299756A1 (en) * 2021-03-09 2024-01-03 JCR Pharmaceuticals Co., Ltd. Method for producing antibody-lysosomal enzyme fusion protein
US20240191179A1 (en) * 2021-04-23 2024-06-13 Kyowa Kirin Co., Ltd. Method for suppressing production of degradation products
TW202241924A (zh) * 2021-04-23 2022-11-01 大陸商和鉑醫藥（上海）有限責任公司 一種雙特異性抗體的純化方法
WO2022272119A2 (en) * 2021-06-25 2022-12-29 The Board Of Trustees Of The University Of Illinois Synthetic toolkit for plant transformation
JP2024539136A (ja) * 2021-10-19 2024-10-28 アルテオジェン・インコーポレイテッド ＩｇＧ Ｆｃドメインを有する融合タンパク質の精製方法
WO2024076990A1 (en) * 2022-10-03 2024-04-11 Therini Bio, Inc. Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
CN117990807B (zh) * 2022-11-07 2024-09-24 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体电荷异质性的检测方法
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法
WO2025029614A1 (en) * 2023-07-28 2025-02-06 Amgen Inc. A method for equilibrating a chromatography medium

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2288600C (en) 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
CA2430182C (en) 2000-12-14 2011-01-25 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
WO2002051870A2 (en) 2000-12-22 2002-07-04 GRAD, Carole Legal Representative of KAPLAN, Howard Phage display libraries of human vh fragments
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
ES2315664T3 (es) 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
CN1922210A (zh) 2003-12-19 2007-02-28 健泰科生物技术公司 可用作治疗剂的单价抗体片段
AU2005216847B2 (en) * 2004-02-27 2010-04-01 Cytiva Bioprocess R&D Ab A process for the purification of antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
CN100475965C (zh) 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
ES2399075T3 (es) 2006-08-30 2013-03-25 Genentech, Inc. Anticuerpos multiespecíficos
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
DE102008048942B4 (de) 2008-09-25 2011-01-13 Siemens Aktiengesellschaft Anordnung mit einer Wellendichtung
RU2598248C2 (ru) 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
SI2417156T1 (sl) 2009-04-07 2015-06-30 Roche Glycart Ag Trivalentna, bispecifiäśna protitelesa
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
SG185737A1 (en) 2010-05-25 2013-01-30 Genentech Inc Methods of purifying polypeptides
EP2635600B1 (en) * 2010-11-05 2017-06-21 F. Hoffmann-La Roche AG Optimized method for antibody capturing by mixed mode chromatography
RS59589B1 (sr) * 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
EP2766397B1 (en) 2011-10-11 2018-05-30 F.Hoffmann-La Roche Ag Improved assembly of bispecific antibodies
SMT202100621T1 (it) 2012-07-13 2022-01-10 Roche Glycart Ag Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
PE20200607A1 (es) * 2012-09-11 2020-03-10 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
BR112016003196A8 (pt) 2013-08-19 2020-02-04 Hoffmann La Roche método para separar anticorpos biespecíficos
US20160272674A1 (en) * 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of antibodies
DK3116891T3 (da) * 2014-03-10 2020-05-04 Richter Gedeon Nyrt Immunglobulinrensning ved hjælp af forrensningstrin
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos

Also Published As

Publication number Publication date
HUE068564T2 (hu) 2025-01-28
CA3026518A1 (en) 2017-12-21
IL263690A (en) 2019-01-31
WO2017218977A3 (en) 2018-01-18
KR20230113662A (ko) 2023-07-31
JP2022166004A (ja) 2022-11-01
WO2017218977A2 (en) 2017-12-21
JP7564843B2 (ja) 2024-10-09
EP3472177B1 (en) 2024-08-14
EP3472177A2 (en) 2019-04-24
JP2019521986A (ja) 2019-08-08
WO2017218977A8 (en) 2019-03-28
US20190256556A1 (en) 2019-08-22
CN109563124A (zh) 2019-04-02
MX2018015173A (es) 2019-07-04
ES2988363T3 (es) 2024-11-20
SG11201810777WA (en) 2018-12-28
MX2024003651A (es) 2024-04-15
KR20190039929A (ko) 2019-04-16
AU2017286676A8 (en) 2018-12-20
JP2024156655A (ja) 2024-11-06
EP3472177C0 (en) 2024-08-14
HRP20241323T1 (hr) 2024-12-20
AR108800A1 (es) 2018-09-26
AU2024227572A1 (en) 2024-11-14
TW201803902A (zh) 2018-02-01
TWI798179B (zh) 2023-04-11
AU2017286676A1 (en) 2018-12-13
AU2017286676B2 (en) 2024-07-25
BR112018075516A2 (pt) 2019-10-01
IL263690B2 (en) 2023-05-01
IL263690B1 (en) 2023-01-01

Similar Documents

Publication Publication Date Title
IL263690A (en) Purification of multispecific antibodies
IL285366A (en) Multi-specific antigen-binding proteins
HK1257760A1 (zh) 多特異性抗體
PT3268390T (pt) Métodos de purificação de anticorpos biespecíficos
ZA201605660B (en) Multispecific antibodies
PL3227332T3 (pl) Wielospecyficzne przeciwciała
ZA201700880B (en) Polymorphs of selinexor
GB201414823D0 (en) Multispecific antibodies
PL3458100T3 (pl) Selektywna redukcja przeciwciał ze zmodyfikowaną cysteiną
GB201521581D0 (en) Methods of purifying nanostructures
GB201516516D0 (en) Process of manufacture
ZA201808524B (en) Methods of affecting separation
IL248697A0 (en) Methods for purifying antibodies
ZA201903408B (en) Process for purification of pyrazolpyridazines
SG11201607098SA (en) Antibody purification process
SG11201710689TA (en) Process of purifying methionine
SG11201608513WA (en) Novel purification process of gonadotropin
SG10202007893TA (en) Methods of immunotherapy
GB201609314D0 (en) Methods of forming compounds
GB201512678D0 (en) Methods of chemical synthesis
SG11201802755WA (en) Process for purification of methyl methacrylate
ZA201608307B (en) Process for the purification of l-alpha-glycerophosphorylcholine
PT3247481T (pt) Purificação de plastificantes
ZA201902183B (en) Purification process of fviii
GB201604934D0 (en) Purification of DNA